TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the November 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the October 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the September 2025 Update
Category: Elite controllers
-
The April 2024 update to TAG’s listing features eight changes. New Additions Three new studies were added this month. All are protocols being initiated by the U.S. government-funded ACTG Network (formerly known as the AIDS Clinical Trials Group, recently revised to Advancing Clinical Therapeutics Globally). The Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa…
-
The March 2024 revision to TAG’s listing includes 26 updates. The annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver from March 3-6, and the addition of links to results from HIV cure-related studies presented at the meeting typically makes this the busiest month for changes — hence the delay to this…
-
There are twelve updates to the listing this month: four new interventional trials and one observational study have been added (all yet to start recruiting), a planned observational study was withdrawn, a trial of immunomodulators has begun recruiting in China, one trial has shifted to the completed studies table, and links to presentations/publications describing results…
-
Several media outlets are reporting on a newly published study of elite controllers, a rare subset of people with HIV who suppress viral load to low or undetectable levels without treatment. A major impetus for the interest is a finding that one long-term elite controller, Loreen Willenberg, may have cleared all the intact HIV from…
-
One of the most widely discussed and publicized ideas for targeting the HIV reservoir is “kick and kill” or “shock and kill.” The aim is to kick dormant, latent HIV into revealing itself so the cells that contain the virus are visible to the immune system; the kill aspect involves trying to enhance the immune…
-
A number of conferences and workshops related to HIV cure research have taken place over the past several months, many of which can be viewed or learned about online. Links and some brief reports from four events are provided below. Promising Approaches to HIV Remission and Cure HIV cure research was the chosen topic for…
-
In the aftermath of the 22nd International AIDS Conference (AIDS 2018), which took place in Amsterdam in July, there has been some reflecting on the challenges facing the HIV cure research field. The presentations that garnered the most news coverage described disappointing study results, but there were also nuggets of novelty and encouragement to be…
-
Over the past few months, several interesting papers addressing elite control of HIV infection have seen publication. The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T cell counts in the absence of ART has led them to be proposed as a model for a functional cure of HIV infection.…
-
A new example of long-term post-treatment control of HIV viral load was reported this past Monday at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, attracting widespread media attention. Presented by Asier Sáez-Cirión from Institut Pasteur in France, the case involves a teenager who acquired HIV infection perinatally and was…
-
Several recent papers offer perspectives on the possibility of achieving post-treatment control of HIV replication by starting antiretroviral therapy (ART) during acute infection. Interest in this topic has been sharpened by reports about the VISCONTI cohort, a group of individuals in France who all started ART soon after HIV acquisition, maintained treatment for several years,…